Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading SciSparc’s latest clinical update can mean sorting through dozens of SEC exhibits, technical trial data, and shifting cash-runway notes. If you have ever wondered, “How do I track SciSparc insider trading Form 4 transactions before the market reacts?” you are not alone. Biotech filings are dense, and SciSparc’s dual focus on cannabinoid drug trials and hemp-product revenues makes them even more layered.
Stock Titan solves the problem. Our AI dissects every SciSparc quarterly earnings report 10-Q filing, highlights R&D spend, and links trial milestones so you can act quickly. Want the cash-burn figures without scrolling? Need SciSparc annual report 10-K simplified line-by-line? Prefer SciSparc Form 4 insider transactions real-time delivered the moment they hit EDGAR? It’s all here, alongside AI-powered summaries that turn medical jargon into plain language. We also cover every 8-K; search “SciSparc 8-K material events explained” and arrive straight at our tagged excerpts.
Whether you’re monitoring understanding SciSparc SEC documents with AI, comparing drug-development timelines, or checking a SciSparc proxy statement executive compensation, our platform offers:
- Real-time alerts for SciSparc executive stock transactions Form 4
- AI summaries that answer “SciSparc SEC filings explained simply” in seconds
- Complete coverage of S-1s, 10-Ks, 10-Qs, 8-Ks, and more—with direct links to exhibits
- Contextual metrics: dilution risk, patent counts, and trial phase progress
No more digging through 200-page PDFs. Stock Titan’s expert analysis and instant updates transform SciSparc earnings report filing analysis into actionable insight you can trust.
SciSparc announced that shareholders approved all proposals at their adjourned annual general meeting held on June 26, 2025. The meeting resulted in the approval of two significant documents:
- A new amended and restated articles of association
- An updated compensation policy for executive officers and directors
These approvals were obtained with the requisite majority in accordance with Israeli Companies Law and the company's existing articles of association. The proposals were previously detailed in a proxy statement furnished to the SEC on May 21, 2025.
The Form 6-K filing will be incorporated into multiple company registration statements, including several Form F-3s (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408) and Form S-8s (File Nos. 333-278437, 333-225773, 333-286791). The document was signed by Oz Adler, Chief Executive Officer.
SciSparc has filed an amended F-4 registration statement regarding its proposed merger with AutoMax Motors. The merger agreement, initially signed on April 10, 2024, and amended multiple times through May 8, 2025, will result in AutoMax becoming a wholly-owned subsidiary of SciSparc.
Key terms of the merger include:
- AutoMax shareholders and advisor will own approximately 49.99% of SciSparc's share capital post-merger
- SciSparc shareholders will retain approximately 50.01% ownership
- SciSparc will maintain its Nasdaq listing under symbol "SPRC"
- Expected closing in Q3 2025, subject to shareholder and court approvals
A special shareholder meeting is scheduled for August 13, 2025 to vote on: merger approval, new indemnification agreements for directors/officers, executive bonuses contingent on merger closing, and election of new board members. Post-merger, Oz Adler will serve as CEO/CFO, with Dr. Adi Zuloff-Shani as CTO.
SciSparc announced the adjournment of its Annual General Meeting of Shareholders due to lack of quorum on June 25, 2025. The Adjourned Annual Meeting is rescheduled for June 26, 2025, at 8:00 a.m. (Eastern Time) / 3:00 p.m. (Israel time) at the company's Tel Aviv offices.
Key details:
- If quorum is not achieved within 30 minutes of the rescheduled meeting, any number of shareholders present in person, by proxy, or who delivered a proxy card will constitute a quorum
- Previously submitted proxy cards for the original meeting will remain valid for the Adjourned Meeting
- The Form 6-K will be incorporated into multiple registration statements, including Form F-3 and Form S-8 filings
The report was signed by Oz Adler, Chief Executive Officer, on June 25, 2025.
SciSparc Ltd has announced a significant corporate action with a 1-for-21 reverse share split as reported in their Form 6-K filing dated June 28, 2025. This strategic move will consolidate every 21 existing shares into 1 new share.
Key filing details:
- Filing incorporates by reference into multiple registration statements, including Form F-3 (6 filings) and Form S-8 (3 filings)
- Document signed by Oz Adler, who serves as both Chief Executive Officer and Chief Financial Officer
- Company maintains its principal executive offices in Tel Aviv, Israel
- Confirms status as a Form 20-F filer for annual reports
The reverse split announcement suggests a potential strategic effort to meet minimum share price requirements for continued exchange listing or improve the stock's marketability to institutional investors.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
